At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 117 enrolled
Drug / intervention
Camidanlumab Tesirinedrug
Likely dose
Not stated in record
Key inclusion· 6
- ✓Pathologically confirmed classical Hodgkin lymphoma (cHL)
- ✓Relapsed or refractory cHL with at least 3 prior systemic therapy lines (or 2 lines if HSCT-ineligible), including brentuximab vedotin and a checkpoint inhibitor approved for cHL
- ✓Measurable disease by 2014 Lugano Classification
- ✓FFPE tumor tissue block or minimum 10 freshly cut unstained slides available
Key exclusion· 13
- ✕Previous treatment with camidanlumab tesirine
- ✕Allogeneic or autologous transplant within 60 days prior to study start
- ✕Active GVHD (except mild non-neurologic chronic GVHD ≤Grade 1)
- ✕Post-transplantation lymphoproliferative disorders
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
In Brief
A Phase 2 clinical trial evaluating Camidanlumab Tesirine for Relapsed Hodgkin Lymphoma and Refractory Hodgkin Lymphoma. Completed, enrolled 117 participants across 73 sites in 11 countries.
Detailed Summary
The purpose of this study is to evaluate the clinical efficacy and safety of Camidanlumab Tesirine (ADCT-301) in participants with relapsed or refractory Hodgkin Lymphoma (HL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Canada, Czechia, France, Germany, Hungary, Italy, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedAug 2019
Enrollment StartSep 2019
Primary CompletionJan 2023
TodayJul 2026
First PostedAug 12, 2019
Enrollment StartSep 13, 2019
Primary CompletionJan 19, 2023
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 6.9 years ago
Interventions
Camidanlumab Tesirinedrug
Intravenous Infusion